Neurovalens Company Profile

Background

Neurovalens, founded in 2015 by Dr. Jason McKeown and Dr. Paul McGeoch, is a health technology company headquartered in Belfast, Northern Ireland. The company specializes in developing non-invasive neurostimulation devices aimed at addressing prevalent health conditions such as chronic insomnia, anxiety, obesity, and Type 2 diabetes. By leveraging advanced neuroscience, Neurovalens seeks to provide drug-free therapeutic solutions that enhance patient well-being and quality of life.

Key Strategic Focus

Neurovalens is committed to revolutionizing the treatment of metabolic and neurological disorders through non-invasive neurostimulation technology. The company's primary objectives include:

Product Development: Creating medical devices that deliver electrical stimulation to specific brain and nervous system areas without the need for surgical implants.

Regulatory Approvals: Securing certifications from regulatory bodies such as the U.S. Food and Drug Administration (FDA) to ensure the safety and efficacy of their products.

Market Expansion: Introducing their devices to global markets, with a particular emphasis on the United States.

Clinical Research: Conducting rigorous clinical trials to validate the effectiveness of their technology across various health conditions.

Financials and Funding

As of April 2024, Neurovalens has successfully raised approximately £13.1 million in equity funding. The most recent funding round, completed in April 2024, secured £2.1 million from existing investors, including:

Wharton Asset Management: A private family office based in London, established in 1992, with a diversified global venture capital and private equity portfolio.

IQ Capital: A venture capital firm investing in deep-tech sectors such as machine learning, AI, and advanced engineering.

Techstart Ventures: An early-stage technology investor managing £90 million of funds from offices in Edinburgh and Belfast.

Angel CoFund: A venture capital fund partnering with experienced angel investors to support early-stage businesses.

Beltrae Partners Ltd: An all-Ireland corporate finance and private equity firm with investments across various sectors.

Clarendon Fund Managers: A Belfast-based venture capital fund manager overseeing CoFundNI, a £50 million equity fund.

The capital raised is intended to support ongoing clinical trials, product development, and market expansion efforts.

Pipeline Development

Neurovalens has developed a range of products targeting various health conditions:

Modius Sleep: An FDA-cleared device designed to treat chronic insomnia through non-invasive electrical vestibular nerve stimulation. Users wear the headset for 30 minutes before bedtime to improve sleep quality.

Modius Stress: A device aimed at treating generalized anxiety disorder (GAD) by delivering safe electrical pulses to the head. It received FDA clearance in April 2024.

Vestal: A device targeting obesity, with a global pivotal trial commenced in Q1 2020 and an estimated completion date in Q2 2022.

Vestal DM: A device for Type 2 Diabetes Mellitus (T2DM), with a global pivotal trial that began in Q2 2021 and an estimated completion date in 2023.

These products are in various stages of clinical trials and regulatory approval processes.

Technological Platform and Innovation

Neurovalens' proprietary technology focuses on non-invasive neurostimulation to modulate brain and nervous system activity. Key aspects include:

Electrical Vestibular Nerve Stimulation (VeNS): Utilizing gentle electrical pulses to stimulate the vestibular nerve, influencing brain regions responsible for sleep, anxiety, and metabolic functions.

Non-Invasive Delivery: Devices are designed to deliver therapeutic stimulation without the need for surgical implants, enhancing patient comfort and compliance.

Clinical Validation: The technology is supported by extensive clinical trials demonstrating its efficacy and safety across multiple health conditions.

Leadership Team

Neurovalens is led by a team of experienced professionals:

Dr. Jason McKeown: Chief Executive Officer and co-founder, with a background in neuroscience and a focus on developing non-invasive neurostimulation therapies.

Dr. Paul McGeoch: Co-founder, contributing his expertise in neurology to the company's product development and clinical research initiatives.

Chris McCabe: Chief Technology Officer, overseeing the technological development and innovation of the company's product portfolio.

Sinead Watson: Chief Regulatory Officer, managing regulatory affairs and ensuring compliance with medical device standards.

Competitor Profile

Market Insights and Dynamics

The global neurostimulation devices market is experiencing significant growth, driven by increasing prevalence of neurological disorders and a demand for non-invasive treatment options. The market encompasses various applications, including pain management, epilepsy, depression, and sleep disorders.

Competitor Analysis

Neurovalens operates in a competitive landscape with several key players:

Muse Headband: Developed by InteraXon, this device uses EEG technology to monitor brainwaves and provide real-time feedback for meditation and relaxation.

Flow Neuroscience Headset: Utilizes transcranial direct current stimulation (tDCS) to treat depression, offering a non-invasive alternative to traditional therapies.

Oura Ring: A wearable ring that tracks sleep patterns, heart rate variability, and body temperature to provide insights into overall health and recovery.

Dreem Headband: Monitors brain waves and sleep patterns to personalize sleep sounds and optimize sleep quality.

These competitors focus on various aspects of mental health and wellness, employing different technologies to achieve their therapeutic goals.

Strategic Collaborations and Partnerships

Neurovalens has established partnerships with several research institutions to advance its clinical research:

Ulster University: Collaborated on clinical trials for the Modius Stress device targeting anxiety treatment.

University of California, San Diego (UCSD): Partnered on studies related to post-traumatic stress disorder (PTSD) treatments.

University College Dublin (UCD): Conducted pilot studies for Type 2 Diabetes Mellitus treatments.

These collaborations enhance the scientific validation and credibility of Neurovalens' products.

Operational Insights

Neurovalens differentiates itself through its focus on non-invasive, drug-free therapeutic solutions for common health conditions. The company's commitment to rigorous clinical research and obtaining regulatory approvals positions it as a credible player in the health-tech industry. By addressing unmet needs in the treatment of insomnia, anxiety, obesity, and diabetes, Neurovalens aims to capture significant market share and improve patient outcomes.

Strategic Opportunities and Future Directions

Looking ahead, Neurovalens plans to:

Expand Product Portfolio: Continue developing and seeking approvals for devices targeting additional health conditions.

Enhance Market Penetration: Strengthen its presence in the U.S. market and explore opportunities in other regions.

Pursue Strategic Partnerships: Collaborate with healthcare providers and insurers to integrate their devices into standard treatment protocols.

Invest in Research and Development: Advance the scientific understanding and technological capabilities of non-invasive neurostimulation.

By leveraging its current strengths and focusing on innovation, Neurovalens is well-positioned to achieve its future objectives and make a significant impact in the health-tech industry.